adMare Industry Builder Series featuring Dr. Alan Rigby: Shaping the Future of Cancer Therapies with Epitopea

Join us on Thursday, January 30th at 12 p.m. ET, for an adMare Industry Builder Series webinar featuring Dr. Alan Rigby, CEO of Epitopea. Dr. Rigby will share his extensive entrepreneurial journey, having founded and led multiple biotech ventures focused on oncology innovation. Now at the helm of Epitopea, he is driving the development of accessible, off-the-shelf RNA immunotherapies that aim to transform patient outcomes in cancer treatment.

Epitopea is at the forefront of oncology innovation, focusing on creating precision therapies that offer durable benefits for patients with hard-to-treat cancers. With a mission to transform patient responses and improve lives, Epitopea is leveraging cutting-edge RNA technologies to redefine cancer treatment.

About Dr. Alan Rigby
Dr. Alan Rigby is an experienced biotech founder and oncology innovator. As the co-founder and former CEO of HiberCell, he spearheaded efforts to prevent cancer relapse through targeting stress response pathways in dormant tumour cells, securing over $250M USD in funding. Dr. Rigby's extensive career includes leadership roles at Warp Drive Bio, Synta Pharmaceuticals, and Eli Lilly and Company, where he advanced numerous drug discovery and development programs.

With a PhD in Biochemistry from Western University, Dr. Rigby has also held academic positions at Harvard Medical School, focusing on computational drug discovery and target validation. His leadership in Epitopea is driving the next wave of cancer immunotherapy innovations.